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Partial lung lavagefor the same mutation in CSF2RA. We speculate that the Mycoplasma pneumoniae pneumonia
might have triggered the clinical presentation. While a good response to serial partial lung
lavage was noticed, the ultimate outcome is uncertain.
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Hereditary pulmonary alveolar proteinosis (PAP) is caused
by abnormalities in either the alpha or the beta chains of
the granulocyte-macrophage colony-stimulating factor
(GM-CSF) receptor due to mutations in their genes (CSF2RA
and CSF2RB). Defective GM-CSF signaling causes failure in
surfactant clearance by alveolar macrophages leading to
alveolar accumulation of surfactant lipids and proteins.1 So
far only 13 patients have been reported 5 of them with beta
chain abnormalities,2e4 including two asymptomatic
siblings and one adult onset case.5 It has been speculated
that the great variability in the clinical presentation may be
due to additional factors altering surfactant homeostasis
and so triggering the clinical onset and/or its severity.1,2
Whole-lung lavage (WLL) remains the preferred therapy.2
As this technique has limitations in young children with
small airways alternative methods such as partial-lung
lavage (PLL) have been developed.6e8 We report a 3-year-
old girl with hereditary PAP caused by abnormal alpha chain
of the GM-CSF receptor associated with Mycoplasma
pneumoniae pneumonia, with a good response to serial PLL.
Investigation of several family members disclosed that both
the patient and an older asymptomatic sister shared the
same genetic and molecular abnormalities.
A case report
Three-year-old girl, the youngest of three female siblings
born from consanguineous (first cousins) parents of
Moroccan ancestry. Her personal and familial history were
otherwise uneventful, and she had had normal growth
with weight and height the 35th and 75th percentiles. She
presented in September 2010 with six day fever, coughing,
nasal discharge and hypoxemia (TcSaO2 93% breathing
room-air). All remaining family members were symptom-
free. A chest X-ray showed right upper lobe (RUL)
consolidation and a bilateral interstitial pattern (Fig. 1a).
WBC was 17,600 (70% PMNs, 20% lymphocytes, 8.6%
monocytes, 1% eosinophils, 0.2% basophils). Serum C
Reactive Protein 13.1 mg/dl. Serum antibodies to Chla-
mydia, Coxiella and M. pneumoniae were all negative.
Total serum antibody M. pneumoniae was below 1/80
(SERODIA-MYCO II, Japan). She was administered oral
azithromycin and received oxygen supply for three days
and was discharged 5 days after admission. Three weeks
later clinical worsening with increasing cough, breath-
lessness and hypoxemia (TcSaO293% on room air) were
noted. A chest X-ray showed a bilateral reticulonodular
pattern without RUL consolidation (Fig. 1b). She was
treated with antibiotics and antituberculosis drugs until
work-up for Mycobacteria proved to be negative. On
bronchoalveolar lavage (BAL) a serum-like liquid with
abundant macrophages and scarce neutrophils wasrecovered. Serum antibody titer to M. pneumoniae was
positive (equal or higher than 1/1280). In November 2010
she was admitted again with polypnea 64/min, breath-
lessness on mild exertion and severe hypoxemia (TcSaO2
82%e85% on room air). She required oxygen supply 1e3 l/
min. Her weight had dropped to the 10th percentile, but
her general condition was otherwise good. Her tempera-
ture was 37.2, she was pale, and had mild bilateral
decreased breath sounds on chest examination. A chest
CT-scan showed a striking bilateral “crazy-paving” pattern
(Fig. 1c). On BAL a milky liquid (Fig. 1d) with granular
proteinaceous periodic acid-Schiff (PAS) positive material
was recovered, supporting the diagnosis of PAP which was
confirmed by surgical pulmonary biopsy (Fig. 1e and f).
Table 1 shows a summary of the clinical progress. Molec-
ular genetics investigation was done in the “Rare Lung
Disease Network”, Cincinatti Children’s Hospital Medical
Center (Dr. B.Trapnell) once informed consent was ob-
tained. It showed blood leukocyte abnormalities suggest-
ing defective GM-CSF receptor: no GM-CSF dependent
phosphorylation of STAT5, increased serum GM-CSF
concentration (73.66 pcg/ml), undetectable GM-CSF
receptor alpha-chain. The patient was found be homozy-
gous for two mutations in the CSF2RA: c.50C > G
(p.Ala17Gly) in exon 3, and c.586G > C (p.Gly196Arg) in
exon 7. GM-CSF autoantibody testing was negative.
She underwent PLL in December 2010 andMarch 2011with
a 1-week interval between the right and left lung lavages. An
Olympus 3.6mm bronchoscope was passed through a 5.5 mm
endotracheal tube at the theater and 20ml 0.9%warm saline
aliquots were flushed into every pulmonary segment, until
the recovered fluid was clear. The first procedure could not
be completed as the patient developed severe hypoxemia.
The aliquots volume was decreased to 15 ml and the
remaining procedures were well tolerated. The total infused
volume at the procedures ranged from 150 to 250 ml, 50%e
75% being recovered. They lasted for about 2 h and the
patient required oxygen supply for 24 h with clear improve-
ment subsequently. The outcome of all the procedures was
similar. She was asymptomatic 3 weeks after the last lavage
with TcSaO2 98% breathing room air, and her chest-ray
changes had improved.
The investigation of the family showed that the parents
and one of the patient’s sisters were heterozygous for both
mutations, the STAT5 phosphorylation index was normal
and GM-CSF receptor alpha and beta proteins were detec-
ted. The other sister aged 7 years was also found to be
homozygous for both mutations (Fig. 2). GM-CSF dependent
STAT5 phosphorylation and the GM-CSF receptor alpha-
chain were undetectable. However she had had not signif-
icant symptoms, her physical examination was unremark-
able and her TcSaO2 was 98% on room air. We agreed with
the parents to keep her under regular follow-up postponing
further investigations as long as she remained symptom-
free.
Figure 1 Pulmonary alveolar proteinosis (PAP) diagnosis. (a) Chest X-ray demonstrating right upper lobe consolidation with
a bilateral interstitial pattern, and (b) bilateral reticulonodular pattern. (c) Sagittal CT-scan showing a “crazy-paving” pattern. (d)
Milky-looking liquid recovered at BAL. (e) Alveoli full of granular eosinophilic PAS þ material (optic microscope). No interstitial
involvement. (f) Lamellar bodies (electronic microscope).
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PAP is mostly an autoimmune condition in children,
hereditary cases being less than 6%.2 Alveolar structure is
maintained in the latter, unlike surfactant production
disorders, and they mimic the autoimmune-mediated
cases both in clinical presentation and their good
response to pulmonary lavage.3 Genetic cases are trans-
mitted as an autosomal recesive trait, by several disease-causing mutations with variable penetrance. The diagnosis
of the disease in our symptomatic case prompted the
finding of the same mutations in her asymptomatic sister,
both being homozygous for pAla117Gly and pGly196Arg.
The latter has been previously reported in two siblings
with PAP, and the abnormality of the CSF2RA was repro-
duced in in vitro studies. The mutation alters one of the
potential sites of N-glycosilation required for GM-CSF
receptor activation.9
In symptomatic cases of hereditary PAP the onset the
symptoms often occurs 1e2 years before the diagnosis is
suspected, and failure to thrive is common.2 The previous
“silent” period may range from weeks to years, and it has
been speculated that its duration may depend on the
Table 1 Evolution of clinical indicators, additional tests and treatment.
September 2010 October 2010 November 2010
Clinical findings Fever, cough,
nasal discharge
Cough breathleness Breathleness, tachypnea
TcSao2%, room air 93 93 85
Chest imaging RUP consolidation,
interstitial pattern
No RUP consolidation,
reticulonodular pattern
CT-scan “crazy-paving”
pattern
BAL macroscopic
microscopic
Serum-like macrophages,
neutrofils
Milky PAS þ material
Antibody titer to
M. pneumoniae
<1/80 >1/1280
Treatment O2 azithromycin, O2 azithromycin, anti TB drugs O2 Partial lung lavage
Hereditary pulmonary alveolar proteinosis 137extent of preserved macrophage function by receptor
intact chain-mediated signaling and/or factors other than
GM-CSF.5 Other hitherto undefined agents altering
surfactant homeostasis could contribute to the wide clin-
ical spectrum of the disease.2 The clinical presentation in
our patient was abrupt and was associated with M. pneu-
moniae pneumonia. Macroscopic and microscopic
appearance of the first BAL was not suggestive of PAP. The
older sister sharing the same molecular-genetic pattern
remained completely asymptomatic and while she was not
tested for M. pneumoniae it is unlikely she was infected.
Infection often occurs in PAP, being difficult to ascertain
whether it works as a trigger or is a mere complication of
the disease. Cases following Cytomegalovirus, Mycobacte-
rium tuberculosis, Nocardia spp, Pneumocystis jiroveci
have been reported, and in some either quantitative or
functional macrophage deficiency have been found.1,10 In
another case following Epstein Barr virus infection auto-
antibodies to GM-CSF were present.11 M. pneumoniae
infection may disrupt surfactant homeostasis by a number
of pathways (intraalveolar fibrin accumulation, type 2Figure 2 Distribution of the CSF2RA mutation in the studied
family.pneumocytes hyperplasia, and defective surfactant
composition and function),12,13 thus we speculate the M.
pneumoniae infection may have triggered the onset of the
clinical symptoms.
PLL has been proposed as an alternative to WLL espe-
cially in young children in whom the latter is often tech-
nically difficult or impossible.6e8 Hypoxia and
hemodynamic instability are common probably due to loss
of surfactant activity, in lavaged and neighboring areas
subject to leaks of the inflowed saline.6 We lavaged the
most affected segments occluding them at the end of the
bronchoscope while the remaining lung was ventilated.
Hypoxia correlated with the aliquot volumes and resolved
when we cut them down.
The ultimate prognosis of the disease is uncertain. In
the only published study on 8 children with CSF2RA
mutations most symptomatic cases still required oxygen
with a 1e3 year follow-up, one had died, and one was
symptom-free.2 Our patient required two PLL over six
months with good clinical response, becoming asymptom-
atic and not requiring oxygen although chest X-rays
remained abnormal. Our patient’s sister remained
symptom-free despite her molecular-genetics pattern
suggested mild or subclinical PAP, similarly to other two
reported cases who remained asymptomatic with a 3 years
and 9 months follow-up.2 Careful monitoring of patients at
risk to develop clinical PAP could help ascertain those
factors conditioning the onset and/or the severity of the
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